Lineage Cell Therapeutics Inc

ASE:LCTX   3:59:51 PM EDT
+0.10 (+8.77%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)210.49M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$3.8 Million
Adjusted EPS-$0.04
See more estimates
10-Day MA$1.19
50-Day MA$1.41
200-Day MA$1.50
See more pivots

Lineage Cell Therapeutics Inc Stock, ASE:LCTX

2173 Salk Avenue, Suite 200, Carlsbad, California 92008-7354
United States of America
Phone: +1.510.521.3390
Number of Employees: 61


Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.